Crizotinib and Ceritinib Induce Apoptosis and Necrosis in Primary Rat Hepatocytes with Distinct Capacity by Salminen, Alec T
University of Arkansas, Fayetteville
ScholarWorks@UARK
Biomedical Engineering Undergraduate Honors
Theses Biomedical Engineering
5-2016
Crizotinib and Ceritinib Induce Apoptosis and
Necrosis in Primary Rat Hepatocytes with Distinct
Capacity
Alec T. Salminen
University of Arkansas, Fayetteville
Follow this and additional works at: http://scholarworks.uark.edu/bmeguht
Part of the Other Biomedical Engineering and Bioengineering Commons, and the Pharmacy
Administration, Policy and Regulation Commons
This Thesis is brought to you for free and open access by the Biomedical Engineering at ScholarWorks@UARK. It has been accepted for inclusion in
Biomedical Engineering Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please
contact scholar@uark.edu.
Recommended Citation
Salminen, Alec T., "Crizotinib and Ceritinib Induce Apoptosis and Necrosis in Primary Rat Hepatocytes with Distinct Capacity"
(2016). Biomedical Engineering Undergraduate Honors Theses. 23.
http://scholarworks.uark.edu/bmeguht/23
Crizotinib and Ceritinib Induce Apoptosis and Necrosis in Primary Rat Hepatocytes with 
Distinct Capacity 
Alec Salminen 
University of Arkansas, Biomedical Engineering, Fayetteville, AR 72701  
 
 
 
Abstract 
Drug development makes up a major portion of biomedical engineering research interests. The FDA 
oversees the introduction, experimentation, and implementation of all drugs before market approval is 
granted. Even after market approval is granted, the FDA continues to monitor the safety of all drugs. 
Crizotinib and ceritinib are two anaplastic lymphoma kinase (ALK) inhibitors recently approved by the 
FDA. Both drugs are indicated for treatment of non-small cell lung cancers (NSCLC) with abnormal ALK 
gene, and they are approved with a companion diagnostic test that determines ALK abnormality.  
Clinical trial data suggest that crizotinib and ceritinib can cause liver injury, and this information has 
been included in the “Warnings and Precautions” section of their labeling. The mechanism of ALK 
inhibitor induced hepatotoxicity is unknown. This study aimed to observe if crizotinib and ceritinib are 
directly toxic to liver cells. Primary cultured rat hepatocytes were treated with crizotinib and ceritinib at 
clinically relevant concentrations for 4, 8 and 24 h, and apoptosis and necrosis were measured. A ~125% 
to ~150% increase in caspase 3/7 activity was observed at 8 h for ceritinib treated hepatocytes, and 
significant necrosis (~40%) occurred at 24 h. Ceritinib treated hepatocytes also showed remarkable 
cytochrome c release at 4 h, the time point when no cell death was detectable. Crizotinib showed no 
toxicity at 10-fold the maximal blood concentration (Cmax), while ceritinib became toxic at 3-fold Cmax 
and caused ~40% cell death at 6-fold Cmax, indicating that ceritinib, the second-generation ALK 
inhibitor, is significantly more toxic than the first-generation drug crizotinib. These data provide novel 
insights into the mechanisms of ALK inhibitors associated hepatotoxicity. 
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Introduction 
Kinases play a major role in the facilitation of many cell processes in the human body. Kinases act to 
phosphorylate certain proteins in the body, which in turn progresses a signal transduction pathway, with 
the end result being the activation of a certain cellular process.1 There are 500 unique kinases, 150 of 
which are involved in the onset or progression of human disease including cancer. While there is a 
variety of protein kinases in the human body, the target of much drug development research to date is 
tyrosine kinase. Tyrosine kinase, much like any other form of kinase, catalyze the phosphorylation of 
tyrosine residues by transferring a phosphate group from ATP. Tyrosine kinase is known to play a major 
role in biological processes like cell proliferation, differentiation, and survival, as well as disease 
development including diabetes and cancer.2 Due to its role in the development and progression of 
some forms of cancer, tyrosine kinase is a protein of interest in the cancer therapy drug industry. Since 
the discovery of tyrosine kinase’s role in cancer progression, many drugs have gained FDA approval for 
the treatment of cancer through tyrosine kinase inhibition. There are a variety of FDA approved tyrosine 
kinase inhibitors, a novel cancer therapy drug class, to date that treat a spectrum of cancer types. The 
FDA approved the first tyrosine kinase inhibitor imatinib (Gleevec) in May of 2001. Since imatinib’s 
approval, up to the date of this research, the FDA has approved and/or investigated 23 tyrosine kinase 
inhibitors (FDA.gov).  Many of these approved tyrosine kinase inhibitors are still of great interest to the 
FDA due to their unknown nature when concerning off-target toxicity. Most tyrosine kinase inhibitors 
work through competitive inhibition of ATP, resulting in the loss of tyrosine kinase’s phosphorylation 
abilities, and halting the pathway in which the tyrosine kinase lies.3 Since a major function of tyrosine 
kinase is cellular proliferation, a root cause of tumor formation, it is clear to see why the inhibition of 
the protein may aid in cancer therapy.  However, due to the broad spectrum nature of the drug, the 
concerns of off-target toxicity of these drugs is still present. 16 out of the 23 approved tyrosine kinase 
inhibitors have warnings for hepatotoxicity. Five of the 16 warnings are black box warnings, the 
strongest FDA safety warning (FDA.gov). Since there is a clear concern for hepatotoxicity of these drugs, 
the FDA and affiliates are still investigating the severity of the toxicity.  
Crizotinib (trade name Xalkori) is the first generation anaplastic lymphoma kinase (ALK)-positive non-
small cell lung cancer drug. Crizotinib is a kinase inhibitor that blocks the ATP binding site of ALK, halting 
the progression of cancer.4 ALK-Positive Non-Small Cell Lung Cancer tumors are highly dependent of 
ALK, and as a consequence, are very sensitive to ALK inhibition. This ALK inhibition is known to lead to 
an increase in progression-free survival of cancer patients.5 One shortcoming of the drug is its labels 
warning of hepatotoxicity, claiming 0.2% of patients developed fatal hepatotoxicity following drug 
administration.6 The label suggests dose reduction, temporary suspension, or permanent drug 
discontinuation if liver tests indicate drug related hepatotoxicity. Continuous administration of crizotinib 
can result in develop resistance of the drug. Mutations, including changes in the solvent exposed region 
of the ATP-binding pocket or amplification of the ALK fusion gene, lead to inefficacy of the drug; for this 
reason, a seconded generation ALK-Positive Non-Small Cell Lung Cancer drug was formed. Ceritinib 
(trade name Zykadia) acts in a similar way as crizotinib to suppress the progression of ALK-Positive Non-
Small Cell Lung Cancer.7 Ceritinib’s label also warns of hepatotoxicity.8  
Drug development constitutes a large portion of biomedical engineering related research. One very 
important step in the drug development process is checking for efficacy and safety of the drug. The FDA 
closely monitors developing drugs before market approval can be granted. There are many reasons the 
FDA will deny approval of a drug, including adverse side effects. Drug induced side effects come in many 
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forms, some of which can be very serious. A major side effect seen in a variety of drugs is hepatotoxicity. 
The liver plays a major role in the metabolism of drugs, and therefore is susceptible to drug-induced 
damage. Many drug types can take a toll on the liver, resulting in drug-induced liver injury (DILI).9 DILI is 
the leading cause of acute liver failure and one of the most common reasons for drug removal from the 
market.10 The liver has an impressive ability to regenerate upon cell loss, however, many drugs can 
induce cell death at a rate in which the regenerative properties of hepatocytes cannot keep up. When 
concerning cell death, it is important to differentiate the two different forms of cell death; apoptosis and 
necrosis. Apoptosis, commonly referred to as programmed cell death, is a pathway mediated form of 
cell death in which, for the most part, unwanted or unneeded cells are shed to free up space for new 
cells. Apoptosis is essential to healthy tissue formation and upkeep in the human body. In contrast, 
necrotic cell death is non-programmed and accidental in nature which can lead to necrosis.11 While it 
may seem that necrotic cell death is the only harmful form of cell death in the body, over activation of 
apoptosis inducing molecules can lead to unwanted cell death as well. When testing for the mechanism 
behind DILI, it is important to test for both necrosis and apoptosis induction.  
While there is cause for concern for hepatotoxicity with a large portion of tyrosine kinase inhibitors, this 
research primary focuses on first and second generation ALK-Positive Non-Small Cell Lung Cancer drugs 
crizotinib and ceritinib. The hepatotoxicity of supplements and drugs can be gaged using a number of 
assays and accompanying mathematical formulas. Crizotinib and ceritinib are known to induce some 
form of hepatotoxicity, however, the mechanism in which it induces this is unclear. In this research, 
primary rat hepatocytes were incubated in varying dosages of the drugs and three assays/protocols 
were used to gain insight on their role in apoptosis and necrosis; Cytochrome C release for apoptosis, 
Caspase 3/7 production for apoptosis, and LDH release for necrosis.  
Cytochrome C is a key protein in the apoptosis cascade. Apoptosis is characterized by cell shrinkage, 
membrane blebbing, and DNA fragmentation. Release of cytochrome c from the mitochondrial inner 
membrane space to the cytosol is a known indicator of apoptosis.12 Using western blot, it is possible to 
test for cytochrome c release from the hepatocyte’s mitochondrial inner membrane space. Downstream 
from cytochrome c are a family of Cysteine-dependent proteases (termed caspases) that also participate 
in the apoptosis cascade. Caspases act to cleave substrates, propagating the cell death signal until 
apoptosis is initiated. There are many different forms of caspase, however, executioner caspase 3 and 7 
are located near the end of the apoptosis cascade; Increase in their activity is a strong indicator of 
apoptosis.13 In this study, cytochrome c detection with western blot and caspase 3/7 assay were used to 
measure apoptosis of hepatocytes treated with crizotinib and ceritinib.  
The nonprogrammer form of cell death, necrosis, is usually caused by a series of unwanted chemicals or 
conditions that lead to cell swelling and eventually membrane rupturing.14 Necrosis is rarely a wanted 
result of any biological process and due to its fast spreading nature can lead to large scale tissue 
damage. When concerning hepatotoxicity, necrosis can be very dangerous in nature. Cytotoxicity and 
necrosis alike are commonly associated with damage to the cellular membrane. Lactate dehydrogenase 
(LDH)-release assays are common place in the toxicology field as they are accurate when gaging a drug’s 
cytotoxicity level.15 Necrosis levels can be estimated by measuring the amount of LDH release caused by 
the drugs and comparing that to the total LDH in the cell. In this study, LDH-release assay was used to 
measure cell viability loss and necrosis in primary rat hepatocytes treated with crizotinib and ceritinib.  
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In theory, results indicating crizotinib and ceritinib induced apoptosis and necrosis in primary 
hepatocytes at relevant levels would back up the claim that these drugs do in fact have hepatotoxic 
properties. 
 
Materials and Methods 
Hepatocyte Isolation 
Primary rat hepatocytes were isolated following the NCTR Center for Hepatotoxicology SOP, “Isolation 
of Primary Rodent Hepatocytes for Cell Culture Using Collagenase Perfusion” (Version 02/14/2011). The 
use of rats for hepatocyte isolation was approved by the NCTR Institutional Animal Care and Use 
Committee. The cells were cultured as monolayers for 18 h before drug treatment. All experiments were 
completed within 48 h after isolation to ensure that hepatocytes maintain similar functions as under in 
vivo conditions. 
Cytochrome C Release - Western Blot 
Primary rat hepatocytes were cultured in 6 well plates for 18 h before drug testing began. Following the 
18 h culture, culture medium was discarded and cells were carefully washed with PBS twice. The 
medium was replaced with a drug and culture medium mixture. Cells subjected to crizotinib treatment 
were cultured in medium containing 10, 15, 20, 25, and 30 µM concentrations of the drug. One well was 
cultured in DMSO as a control (0 µM crizotinib). Cells subjected to ceritinib treatment were cultured in 
medium containing 4, 6, 8, 10, and 12 µM concentrations of the drug. One well in this test group was 
also cultured in medium containing DMSO as a control (0 µM ceritinib). Hepatocytes in both drug test 
groups were cultured for 4, 8, and 24 h. Following incubation, the drug containing medium was 
discarded and the cells were washed thoroughly with PBS twice (3 ml/ 1 min each time). 200 µl/well 
0.002% digitonin was added to the 6 well plates. Each plate was rocked gently in order to ensure even 
distribution of the digitonin solution. After 5 min, the solution was extracted from each well and placed 
in individual 0.5 ml centrifuge tubes. The samples were labeled and centrifuged at 1000 rpm for 3 min to 
remove floating cells. 150 µl of each of the remaining samples was transferred to a new 0.5 ml tube and 
mixed with 50 µl 4x reduced loading buffer.  The result of the sample preparation protocol was a set of 
36 samples; one sample for each drug concentration at each time point. 10 µl samples were loaded into 
gels and ran for about 1 h. A variety of sample sizes and gel sizes were tested during the 
experimentation process, however, it was concluded that the 4-20% precast polyacrylamide, 15 well, 15 
µl gels resulted in the best outcome. Following protein separation by gel electrophoresis, gel to 
membrane transfer was performed. The transfer process was performed using a Bio-Rad Trans-Blot 
Turbo transfer system with recommended settings for Mini-PROTEAN TGX gels. Membranes were rinsed 
in TBS. Blotting-Grade Blocker #1706404 in TBS was added to a tray in which the membranes were 
placed. The blocking process was completed on a rocker for 1 h at room temperature. The membranes 
were rinsed 3 times in TBS following blocking to remove any residual blocking agent. In order to observe 
cytochrome c, membrane integrity WB antibody cocktail (ab110414) was used as the primary antibody. 
The primary antibody was added to TBS and poured into the tray containing the membrane.  The 
membranes were incubated with the primary antibody overnight (approximately 18 h) on a rocker in the 
fridge. Membranes were rinsed with TBS to remove residual primary antibodies. The secondary 
antibody (Anti-Mouse CY5) was added to TBS and poured into the tray containing the membrane. The 
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membranes were incubated with the secondary antibody on a rocker at room temperature for 1 h. The 
membranes were lightly rinsed with TBS and left to dry. Sufficiently dry membranes were imaged using 
a Amersham Imager 600. 
 
Caspase-Glo® 3/7 Assay 
Promega’s Caspase-Glo© 3/7 Assay was used for caspase 3/7 detection. Primary rat hepatocytes were 
cultured in 96-well plates for 18 h before crizotinib and ceritinib were introduced to the cells. Cells were 
then cultured in drug containing medium at varying times and concentrations as follows: 6, 8, and 10 
µM ceritinib for 4 h; 6, 8, and 10 µM ceritinib for 8 h; 15, 20, and 25 µM crizotinib for 4 h; 15, 20, and 25 
µM crizotinib for 8 h. Caspase-Glo© Reagent was prepared by transferring contents of Caspase-Glo© 
Buffer bottle to the Caspase-Glo© Substrate bottle immediately preceding experimentation. Drug 
containing medium was discarded from the 96-well plates and replaced with 100 µl of culture medium. 
100 µl Caspase-Glo© Reagent was added to each well. 96-well plates were gently mixed for 30 seconds 
before returning to the incubator. The plates were left in the incubator for 3 h. Luminescence of the 
plates were read using a Turner Biosystems Modulus Microplate Reader. 
Lactate dehydrogenase (LDH) Leakage 
Primary rat hepatocytes were cultured in 96-well plates for 18 h before crizotinib and ceritinib were 
introduced to the cells. Cells were then cultured in drug containing medium at varying times and 
concentrations as follows: 0, 2, 4, 6, 8, 10, and 12 µM ceritinib for 8 h; 0, 2, 4, 6, 8, 10, and 12 µM 
ceritinib for 24 h; 0, 5, 10, 15, 20, 25, and 30 µM crizotinib for 8 h; 0, 5, 10, 15, 20, 25, and 30 µM 
crizotinib for 24 h. The following reagents were prepared for the LDH release assay: 
1. buffer (stored at room temperature) 
a. 81.3 mM Tris: 9.83 g/1000 ml 
b. 203.3 mM NaCl: 11.9 g/1000 ml 
c. HCl to adjust pH to 7.2 
2. LDH-1 (stored at -80 C: 1 ml/5 ml tube) 
a. 10 mM: 709.4 mg in 100 ml buffer NADH 
3. LDH-2 (stored at -80 C: 1 ml/5 ml tube) 
a. 85 mM: 935.3 mg in 100 ml buffer monosodium pyruvate 
 
LDH release assay reaction buffer was prepared by mixing 1 ml LDH-1, 1 ml LDH-2, and 48 ml buffer. 10 
µl supernatant per well was taken from the original 96-well plate and added to a new 96-well plate 
(Plate S). 90 µl of the Caspase-Glo© buffer was added to the original 96-well plate and left to incubate 
for 3 h. 10 µl supernatant was removed from the Caspase-Glo© buffer containing plate and placed in a 
new 96-well plate (Plate T). 220 µl LDH release assay reaction buffer was added to the plates. The plates 
were read with using a Biotek Synergy™ 4 Hybrid Microplate Reader reading at 60 s intervals over 3 min. 
The following equations were used to calculate LDH release: 
(
∆𝐴𝑝𝑙𝑎𝑡𝑒 𝑠
∆𝐴𝑝𝑙𝑎𝑡𝑒 𝑡
) ∗ 100%           (1) 
Where; 
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∆𝐴 = 𝐴1 𝑚𝑖𝑛 − 𝐴2 𝑚𝑖𝑛          (2) 
 
Data Analysis 
All data analysis was performed on Microsoft Excel 2016. 
 
Results 
Cytochrome C Release – Western Blot Results 
Western blot is a reproducible and accurate way to identify broad concentrations of certain proteins in a 
cell. The results pictured in Figure 1 represent the cytochrome c release values of hepatocytes treated 
with crizotinib and ceritinib. It is important to note that the drugs were administered at multiples of 
Cmax. Cmax is the peak drug concentration found in the body following administration. This value is 
important in the toxicology field as it is a way to correlate cell culture toxicity to in vivo toxicity. The 
Cmax of ceritinib and crizotinib are 2 µM and 1 µM respectively. All drug concentrations at both time 
points showed some level of cytochrome c translocation. The DMSO control showed a trace amount of 
cytochrome c translocation as well. In the 4 h treatment results, crizotinib induced an increasing amount 
of cytochrome c release from 15 to 20 to 25 *Cmax (Figure 1). There was a drop in cytochrome c release 
at 30 *Cmax. Ceritinib induced an increase in cytochrome c translocation from 3 to 6 *Cmax (Figure 1). 
There was no observable decrease in cytochrome c release at the peak concentration. Following the 8 h 
treatment, crizotinib treated hepatocytes released an increasing amount of cytochrome c from 15 to 20 
to 25 *Cmax that dropped off almost completely in the 30 *Cmax lane (Figure 1). 8 h ceritinib treated 
hepatocytes expressed an increase in cytochrome c release from 3 to 4 to 5 *Cmax that dropped off 
slightly at 6 *Cmax. 
 
 
 
Figure 1. Western blot was ran using hepatocyte culture supernatant following crizotinib and ceritinib treatment. 
Treatment consisted of 4 and 8 h incubation times at varying Cmax as labeled. Membrane integrity WB antibody 
cocktail (ab110414) was used to mark cytochrome c present in the samples. Anti-Mouse CY5 was used to mark the 
primary antibody for imagining. Cytochrome c was identified as bands located around the 12 kDa range as marked 
by the western blot protein ladder. The images seen were taken using a Amersham Imager 600. 
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Figure 2 presents another western blot ran to identify cytochrome c release in crizotinib and ceritinib 
treated hepatocytes. Drug administration concentrations are shown in µM in this figure as opposed to 
Cmax as seen in Figure 1. The 0 µM control lanes for crizotinib treated hepatocytes showed basically no 
cytochrome c release after 4 and 8 h treatments, but did show trace amounts in the 24 h lane (Figure 2). 
At peak concentration (30 µM), crizotinib treated hepatocytes showed a decreasing trend of cytochrome 
c release as time of treatment increased. All control lanes for the ceritinib treated hepatocytes showed 
no cytochrome c translocation. The peak concentration (12 µM) lanes for ceritinib showed a decreasing 
trend of cytochrome c release to the point where there is almost no detectable cytochrome c after 24 h 
treatment (Figure 2). 
 
 
 
Figure 2.  Western blot was ran using hepatocyte culture supernatant following crizotinib and ceritinib treatment. 
Treatment consisted of 4, 8, and 24 h incubation times at varying µM as labeled. Membrane integrity WB antibody 
cocktail (ab110414) was used to mark cytochrome c present in the samples. Anti-Mouse CY5 was used to mark the 
primary antibody for imagining. Cytochrome c was identified as bands located around the 12 kDa range as marked 
by the western blot protein ladder. The images seen were taken using a Amersham Imager 600. 
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Caspase-Glo© 3/7 Assay Results 
Promega’s Caspase-Glo© 3/7 assay is used to estimate caspase activity in a cell. Figures 3 and 4 present 
the assay results for hepatocytes treated with either crizotinib or ceritinib. Crizotinib induced very little 
increase in caspase activity after 4 h treatment. Hepatocytes treated with 15 µM crizotinib for 4 hours 
showed an increase in caspase activity of about 120% (Figure 3). This number decreased to ~115% with 
20 µM of crizotinib and ~110% with 25 µM. The 8 h treated hepatocytes showed a significantly larger 
increase in caspase activity. Hepatocytes treated with 15 µM crizotinib for 8 h showed a ~145% increase 
in caspase activity that increased to about ~175% with 20 µM crizotinib and decreased slightly to around 
~165% with 25 µM crizotinib (Figure 3). 
 
 
Figure 3. Promega’s Caspase-Glo© 3/7 assay was used to estimate caspase activity in crizotinib treated 
hepatocytes. Hepatocytes were incubated with crizotinib for 4 and 8 h at varying concentrations as labeled. 
Positive standard deviation is shown for the 8 h line and negative standard deviation is shown for the 4 h line to 
minimize data overlap. All data values graphed are shown in Tables A2 and A4 located in the appendix.  
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After 4 h treatment, ceritinib induced an initially slightly higher amount of caspase activity in 
hepatocytes when compared to crizotinib. Hepatocytes treated with 6 µM ceritinib for 4 hours 
expressed a ~130% increase in caspase activity that raised to ~135% with 8 µM ceritinib and remained 
steady at ~135% with 10 µM ceritinib (Figure 4). Hepatocytes treated with 6 µM ceritinib for 8 h showed 
a ~120% increase in caspase activity when compared to the control. This number raised to ~140% with 8 
µM ceritinib and ~160% with 10 µM ceritinib (Figure 4).  
 
 
Figure 4. Caspase-Glo© 3/7 assay was used to estimate caspase activity in ceritinib treated hepatocytes. 
Hepatocytes were treated with ceritinib for 4 and 8 h at varying concentrations as labeled. Negative standard 
deviation is shown for the 4 h line and positive standard deviation is shown for the 8 h line to minimize data 
overlap. Data values graphed can be found in Tables A1 and A3 located in the appendix. 
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Lactate dehydrogenase (LDH) Leakage Results 
LDH leakage is a known indicator of necrosis and cell viability loss. LDH leakage assays are used to 
quantify the extent in which cell viability is lost across a cell population. The LDH leakage assay results 
for hepatocytes treated with either crizotinib or ceritinib are located in Figures 5 and 6. Hepatocytes 
treated with crizotinib for 8 h released about 35% of their LDH contents at the maximum concentrations 
tested (30 µM). LDH released from hepatocytes treated with crizotinib concentrations lower than 30 µM 
for 8 h started out at around ~9% (0 µM) and steadily increased to ~18% release at 25 µM (Figure 5). 
Following 24 h of treatment, crizotinib induced a significantly higher amount of LDH release when 
compared to the 8 h treatments. 10 µM crizotinib induced ~30% LDH release after 24 h treatment that 
increased to ~70% at 30 µM (Figure 5). 
 
 
Figure 5. LDH release assay was performed on crizotinib treated hepatocytes as outlined in the materials and 
methods section. Hepatocytes were incubated with crizotinib for 8 and 24 h at varying concentrations as labeled. 
Both data sets show positive standard deviation. Data values can be found in Tables A6 and A8 located in the 
appendix. 
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After 8 h treatment, ceritinib induced no significant increase in LDH release at any of the concentrations 
tested compared to the control (Figure 6). At the maximum concentration tested (12 µM), ceritinib 
induced ~40% LDH release following 24 h treatment. The lower concentrations did not show any 
significant increase in LDH release after 24 h treatment when compared to the control.  
 
 
Figure 6. LDH release assay was performed on ceritinib treated hepatocytes as outlined in the materials and 
methods section. Hepatocytes were incubated with ceritinib for 8 and 24 h at varying concentrations as labeled. 
Both data sets show positive standard deviation. Data values can be found in Tables A5 and A7 located in the 
appendix. 
 
 
Discussion 
When assessing the cytotoxicity of any drug, it is important to narrow down the possible mechanism in 
which the toxicity occurs as well as the drug’s level of toxicity itself. Ceritinib and crizotinib have clear 
warnings for hepatotoxicity on their FDA labels, however, the mechanism and threat level of this claim is 
unknown at the moment. It is also necessary to work in clinically relevant dosages when testing toxicity 
in vitro. To an extent, almost any drug will kill cells in culture at high concentrations; for this reason, the 
Cmax’s of ceritinib and crizotinib were calculated before this study began. Ceritinib has a Cmax of about 
2 µM and crizotinib has a Cmax of about 1 µM. Using these values, it is possible to infer from the in vitro 
results what level of toxicity these drugs might cause in vivo.  
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One mechanism of hepatotoxicity is the translocation of apoptosis inducing proteins such as cytochrome 
c. Apoptosis is a form of cell death that is believed to be programmed and occurs in all healthy tissues in 
the body, however, over activation of the apoptosis cascade can lead to unwanted cell death and 
toxicity. The translocation of cytochrome c from mitochondrial inner membrane space to cytosol is a 
known initiating event of apoptosis. Western blot was used to observe any possible changes in 
cytochrome c levels in the cytosol. Figure 1 shows the western blot results for both crizotinib and 
ceritinib treated hepatocytes at varying times and concentrations. For this protocol, *Cmax was used as 
a measure of concentration to show clinically relevant levels of drug treatment. In Figure 1, crizotinib 
treated hepatocytes showed an increase in cytochrome c leaves from 15 to 25 *Cmax; this is true for 
both the 4 and 8 h treatments. This is especially clear when comparing the bands to that of the control 
(DMSO) which shows little to no cytochrome c. At the 30 *Cmax concentration band, there is a drop in 
cytochrome c levels; this is again true for both the 4 and 8 h treatments. The likely reason for this is that 
necrosis occurred and cytochrome c is released into the cell culture medium and subsequently discarded 
prior to western blot detection. For the hepatocytes treated with ceritinib for 4 h, there is a steady 
increase in cytochrome c levels from 3 to 6 *Cmax. Since there is this steady increase in cytochrome c 
levels, the cells in all concentration columns are still alive, but in the pre-apoptosis state. The 
hepatocytes treated with ceritinib for 8 h show an increase in cytochrome c levels from 3 to 5 *Cmax 
and a decrease at 6 *Cmax. This decrease is again indicative of cell death. When comparing these two 
drugs, it is important to note that while crizotinib did induce more cell death at its highest concentration 
(30 *Cmax), Ceritinib induced cell death at a more clinically relevant concentration (6 *Cmax). 
In Figure 2, a faint increase in cytochrome c release is seen from 4 to 24 h when cells are treated with 
the DMSO control, however, a low level of apoptosis is common in any cell culture, so seeing some 
cytochrome c is not unexpected. Hepatocytes treated with 30 µM crizotinib showed a relatively high 
level of cytochrome c release at the 4 h time point, which declined over the 8 and 24 h time points. The 
results for hepatocytes treated with 12 µM ceritinib showed a similar pattern. 
An increase in caspase activity is another known marker of apoptosis. Caspase is in fact the executor of 
apoptosis. In this study, Promega’s Caspase-Glo© 3/7 assay was used to estimate caspase activity in 
hepatocytes treated with ceritinib and crizotinib. Caspase assay results for crizotinib treated 
hepatocytes are shown in Figure 3. Hepatocytes treated with crizotinib for 4 h showed little to no 
increase in caspase activity (compared to the control) with increase in drug concentration. Hepatocytes 
treated with crizotinib for 8 h showed an initial increase in caspase activity at the 15 µM concentration 
(compared to the control) that increased further when the drug concentration was raised to 20 µM. 
However, the caspase activity differed very little from the 20 µM concentration to the 25 µM 
concentration. These results imply that crizotinib did not induce an increase in caspase activity at any 
concentration with the 4 h treatment, thus there was no increase in apoptosis activity. The hepatocytes 
treated with the drug for 8 h, however, did show a 2.5 to 2.75-fold increase in caspase activity, 
indicating that there was indeed an increase in apoptosis activity in the cell population. Caspase activity 
assay results for ceritinib treated hepatocytes are seen in Figure 4. Much like the crizotinib results, the 4 
h ceritinib treatment did not seem to increase caspase activity in hepatocytes. The 8 h treated 
hepatocytes saw a 2.25 to 2.5-fold increase in caspase activity compared to the control, indicating that 
apoptosis was induced at all concentrations tested.  
Another mechanism for cytotoxicity is the initiation of necrosis. Necrosis is generally believed to be a 
non-programed form of cell death that can lead to catastrophic tissue damage. Due to its dangerous 
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nature, necrosis is a strong indicator of cytotoxicity. In this study, necrosis was estimated using a Lactate 
Dehydrogenase (LDH) leakage assay. LDH leakage is a known indicator of cell viability loss and necrosis. 
LDH leakage assay results for hepatocytes treated with crizotinib are shown in Figure 5. After 8 hours of 
crizotinib treatment, the hepatocytes showed a slight increase in LDH leakage at the 10 µM 
concentration that increased to about 37% LDH leakage at the highest concentration tested (30 µM). 
Hepatocytes treated with crizotinib for 24 hours showed a much more dramatic increase in cell viability 
loss, starting out at 30% for the 10 µM concentration and ending up around 70% for the 30 µM 
concentration. Considering these values are 10 to 30 *Cmax, the induction of necrosis by crizotinib is not 
unexpected and is not a cause for great concern.  Hepatocytes treated with ceritinib for 8 hours showed 
only a slight increase in LDH leakage with increase in drug concentration (Figure 6). After 24 hours of 
ceritinib treatment, hepatocytes showed significant increase in LDH leakage at the lowest concentration 
and over 40% cell viability loss at the highest concentration. Unlike crizotinib, ceritinib was tested at 
clinically relevant levels, therefore seeing hepatotoxicity at just 2 *Cmax is of clinical concern.  
When addressing all the results presented in the study, it is shown that both drugs do induce an 
observable level of apoptosis and necrosis in primary rat hepatocytes. While these three cytotoxicity 
assays are separate from each other, comparing all results side-by-side provides some insight into the 
mechanism in which these drugs induce hepatotoxic effects. The hepatocytes treated with ceritinib saw 
little to no necrotic cell death at lower concentrations after the 8 h treatment (Figure 5), however, these 
same concentration levels and treatment times showed an increase in caspase activity (Figure 3) and an 
increase in cytochrome c translocation (Figure 1). This observation leads to the conclusion that even 
though crizotinib did not induce large scale necrosis at lower concentrations and treatment times, the 
drug did initiate apoptosis. Similarly, ceritinib treated hepatocytes showed basically no necrotic cell 
death following 8 h treatment (Figure 6). Once again, however, ceritinib did induce caspase activity 
(Figure 4) and translocation of cytochrome c (Figure 1), indicating the initiation of apoptosis prior to 
large scale necrosis. As previously addressed, the promotion of apoptosis is still harmful to healthy 
tissue, and is indicative of hepatotoxicity. When comparing the two drugs, ceritinib showed 
hepatotoxicity at concentrations as low as 2 *Cmax, while crizotinib did not show signs of hepatotoxicity 
until concentrations upwards of 10 *Cmax were administered. This leads to the conclusion that ceritinib 
is more harmful in clinical situations than crizotinib. Overall, these drugs are used for a type of cancer 
(Non-Small Cell Lung Cancer) that can be very aggressive, therefore the hepatotoxicity measurement 
presented in this study should be weighed against the therapeutic benefits of these two drugs prior to 
discontinuation. It should also be noted that data presented here are preliminary in nature. Further 
tests with hepatocytes from more animals will be needed to confirm the major findings.   
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Appendix 
Caspase-Glo© 3/7 Assay Raw Data 
Table A1. Sample of complete data collection and interpretation for a single Caspase-Glo© 3/7 Assay run. 
Hepatocytes were treated with Ceritinib (Drug 51) for 4 h prior to Caspase assay. All data interpretation was 
completed using Microsoft Excel 2016. Data collected and formulated was used in part to create Figure 4. 
 Date 6/22/2015     
 Rat Sex Female     
 Rat DOB 3/28/2014     
 Rat BW 490     
 Perfusion Results Good     
         
 Drug 51     
 Time 4h     
 Caspase 3/7       
 
 
Raw Data Readings 
 1 2 3 4 5 6 
 218164 202533 229096 277522 226874 269973 
 203087 167948 215347 219667 210465 209550 
 188968 240443 195042 276729 230772 261709 
 186947 230380 249536 355736 242666 240457 
 254666 247782 214500 294477 199577 212613 
 227429 247962 222964 235754 189902 238168 
 210007 323971 195310 282332 188281 228480 
 243681 272886 226169 368942 270629 278299 
  
Average 216618.625 241738.125 218495.5 288894.875 219895.75 242406.125 
µM 0 4 6 8 10 12 
         
% Control   111.5961866 100.8664421 133.3656674 101.5128547 111.9045627 
       
 7 8 9 10 11 12 
 244682 226736 289768 232294 259162 293748 
 220095 228737 220436 316974 192765 256128 
 215500 195530 436466 214310 195455 304574 
 244292 218645 346314 213947 263242 293471 
 203268 269711 207980 198271 183386 358285 
 225300 215590 241242 234911 247987 281113 
 215239 197827 276710 214601 212335 266855 
 239518 232951 338936 281703 213079 290193 
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Average 225986.75 223215.875 294731.5 238376.375 220926.375 293045.875 
µM 0 4 6 8 10 12 
        
% Control  98.77387723 130.4198144 105.4824564 97.76076474 129.6739189 
       
 13 14 15 16 17 18 
 35098.1 95386.7 63470.8 82373.5 139969 181033 
 77370.5 103437 34532.4 51032.3 143954 198995 
 81827.6 121658 61093.8 107466 142860 144442 
 117034 123012 115534 118703 139311 147870 
 98432.5 131614 126595 136754 136681 143247 
 25927.5 134169 123243 134945 126328 153216 
 42469.2 125564 128670 138971 144783 173241 
 28868.6 133894 145579 130167 123738 196283 
  
Average 63378.5 121091.8375 99839.75 112551.475 137203 167290.875 
µM 0 4 6 8 10 12 
        
% Control  191.0613812 157.5293672 177.5862083 216.48193 263.9552451 
       
 
Average % of 
control 133.8104817 129.6052079 138.811444 138.5851831 168.5112422 
 
Concentration 
(MM) 4 6 8 10 12 
 STDEV 49.99351986 28.34024449 36.35904455 67.48664255 83.1330606 
 
 
 
 
 
 
 
 
 
 
 
 
18 
 
Table A2. Key data collected for Caspase-Glo© 3/7 assay on Crizotinib (Drug 25) treated hepatocytes. Hepatocytes 
were treated in Crizotinib for 4 h prior to Caspase assay. Data collected and formulated was used in part to create 
Figure 3. 
Date 6/22/2015     
Rat Sex Female     
Rat DOB 3/28/2014     
Rat BW 490     
Perfusion Results Good     
        
Drug 25     
Time 4h     
Caspase 3/7       
      
Average % of 
control 114.6144063 120.9937006 121.7584142 115.8751086 112.579917 
Concentration (uM) 10 15 20 25 30 
STDEV 29.88424329 25.82083019 6.127731756 8.49012424 25.72372623 
 
 
Table A3. Key data collected for Caspase-Glo© 3/7 assay on Ceritinib (Drug 51) treated hepatocytes. Hepatocytes 
were treated in Ceritinib for 8 h prior to Caspase assay. Data collected and formulated was used in part to create 
Figure 4. 
Date 6/22/2015     
Rat Sex Female     
Rat DOB 3/28/2014     
Rat BW 490     
Perfusion Results Good     
        
Drug 51     
Time 8h     
Caspase 3/7       
      
Average % of 
control 112.2934356 121.1526027 144.4357085 155.3062186 161.5224722 
Concentration (uM) 4 6 8 10 12 
STDEV 20.63367204 35.17921751 18.80838098 49.62077058 46.23077041 
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Table A4. Key data collected for Caspase-Glo© 3/7 assay on Crizotinib (Drug 25) treated hepatocytes. Hepatocytes 
were treated in Crizotinib for 8 h prior to Caspase assay. Data collected and formulated was used in part to create 
Figure 3. 
Date 6/22/2015     
Rat Sex Female     
Rat DOB 3/28/2014     
Rat BW 490     
Perfusion Results Good     
        
Drug 51     
Time 8h     
Caspase 3/7       
      
Average % of 
control 112.2934356 121.1526027 144.4357085 155.3062186 161.5224722 
Concentration (uM) 4 6 8 10 12 
STDEV 20.63367204 35.17921751 18.80838098 49.62077058 46.23077041 
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LDH Release Assay Raw Data 
Table A5. Sample of complete raw data collection and interpretation of LDH release for Ceritinib (Drug 51) treated 
hepatocytes. Hepatocytes were treated with Ceritinib for 8 h prior to LDH release assay. All data interpretation was 
done using Microsoft Excel 2016. Data collected and formulated was used in part to create Figure 6. 
Date 6/22/2015       
Rat Sex Female       
Rat DOB 3/28/2014       
Rat BW 490       
Perfusion Results Good       
          
          
Drug 51       
LDH Release Assay         
Time 8h       
        
Replicate 1 
Raw Data - Plate S 
 
 
 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 0.829 0.828 0.843 0.83 0.825 0.844 0.842 0.825 0.832 0.83 0.833 0.839 340 Read#1
B 0.841 0.836 0.827 0.825 0.829 0.833 0.832 0.833 0.826 0.833 0.829 0.816 340 Read#1
C 0.843 0.825 0.83 0.821 0.831 0.835 0.825 0.834 0.815 0.834 0.827 0.839 340 Read#1
D 0.815 0.819 0.823 0.83 0.826 0.838 0.835 0.826 0.831 0.836 0.845 0.843 340 Read#1
E 0.835 0.827 0.83 0.838 0.827 0.852 0.833 0.843 0.831 0.83 0.836 0.835 340 Read#1
F 0.819 0.823 0.834 0.821 0.833 0.843 0.833 0.832 0.826 0.834 0.828 0.835 340 Read#1
G 0.829 0.828 0.837 0.829 0.831 0.832 0.83 0.841 0.838 0.836 0.84 0.841 340 Read#1
H 0.839 0.825 0.831 0.828 0.821 0.832 0.84 0.83 0.838 0.837 0.84 0.848 340 Read#1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.792 0.793 0.805 0.796 0.786 0.803 0.804 0.787 0.794 0.79 0.792 0.759 340 Read#6
B 0.806 0.806 0.792 0.784 0.795 0.796 0.801 0.801 0.79 0.796 0.791 0.714 340 Read#6
C 0.805 0.795 0.797 0.792 0.796 0.804 0.797 0.802 0.779 0.799 0.788 0.774 340 Read#6
D 0.78 0.788 0.793 0.798 0.792 0.806 0.802 0.786 0.791 0.797 0.807 0.77 340 Read#6
E 0.8 0.792 0.798 0.802 0.793 0.821 0.801 0.807 0.795 0.791 0.801 0.746 340 Read#6
F 0.793 0.792 0.795 0.792 0.805 0.806 0.804 0.803 0.795 0.799 0.792 0.754 340 Read#6
G 0.805 0.801 0.804 0.792 0.799 0.789 0.797 0.807 0.802 0.801 0.801 0.767 340 Read#6
H 0.805 0.79 0.796 0.793 0.772 0.774 0.795 0.79 0.798 0.799 0.806 0.792 340 Read#6
0.037 0.035 0.038 0.034 0.039 0.041 0.038 0.038 0.038 0.04 0.041 0.08
0.035 0.03 0.035 0.041 0.034 0.037 0.031 0.032 0.036 0.037 0.038 0.102
0.038 0.03 0.033 0.029 0.035 0.031 0.028 0.032 0.036 0.035 0.039 0.065
0.035 0.031 0.03 0.032 0.034 0.032 0.033 0.04 0.04 0.039 0.038 0.073
0.035 0.035 0.032 0.036 0.034 0.031 0.032 0.036 0.036 0.039 0.035 0.089
0.026 0.031 0.039 0.029 0.028 0.037 0.029 0.029 0.031 0.035 0.036 0.081
0.024 0.027 0.033 0.037 0.032 0.043 0.033 0.034 0.036 0.035 0.039 0.074
0.034 0.035 0.035 0.035 0.049 0.058 0.045 0.04 0.04 0.038 0.034 0.056
Read 6 - Read 1
Averages: 0.033 0.03175 0.034375 0.034125 0.035625 0.03875 0.033625 0.035125 0.036625 0.03725 0.0375 0.0775
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
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Raw Data - Plate T 
 
 
 
 
 
 
Replicate 2 
Raw Data - Plate S 
 
 
1 2 3 4 5 6 7 8 9 10 11 12
A 0.97 1.064 1.026 1.014 1.029 1.047 1.024 1.045 1.054 1.041 1.057 1.056 340 Read#1
B 0.976 1.02 1.027 1.019 1.027 1.03 1.032 1.054 1.08 1.046 1.046 1.06 340 Read#1
C 1.001 1.009 1.022 1.013 1.017 1.025 1.018 1.038 1.042 1.032 1.04 1.057 340 Read#1
D 0.996 0.992 1.002 0.996 1.01 1.015 1.008 1.028 1.04 1.025 1.038 1.06 340 Read#1
E 1.002 0.998 1.006 0.999 0.993 1.011 1.005 1.02 1.029 1.006 1.03 1.045 340 Read#1
F 0.998 0.994 1.004 0.999 0.994 1.009 1.008 1.019 1.032 1.012 1.039 1.053 340 Read#1
G 0.992 0.989 0.998 1.004 0.997 1.008 1.005 1.02 1.029 1.021 1.031 1.045 340 Read#1
H 0.956 0.975 0.976 0.984 1.004 0.995 0.999 1.006 1.028 1.014 1.032 1.021 340 Read#1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.628 0.869 0.834 0.751 0.818 0.793 0.712 0.853 0.842 0.802 0.849 0.843 340 Read#6
B 0.672 0.84 0.865 0.781 0.838 0.766 0.776 0.898 0.885 0.797 0.832 0.848 340 Read#6
C 0.758 0.817 0.843 0.8 0.813 0.763 0.746 0.86 0.839 0.743 0.831 0.85 340 Read#6
D 0.753 0.795 0.809 0.744 0.805 0.775 0.746 0.843 0.83 0.741 0.817 0.853 340 Read#6
E 0.779 0.796 0.805 0.787 0.767 0.76 0.755 0.823 0.802 0.709 0.823 0.836 340 Read#6
F 0.767 0.8 0.802 0.79 0.775 0.775 0.772 0.832 0.806 0.722 0.829 0.844 340 Read#6
G 0.767 0.781 0.794 0.804 0.783 0.789 0.775 0.826 0.822 0.782 0.829 0.842 340 Read#6
H 0.722 0.761 0.766 0.77 0.787 0.772 0.758 0.803 0.816 0.809 0.83 0.797 340 Read#6
0.342 0.195 0.192 0.263 0.211 0.254 0.312 0.192 0.212 0.239 0.208 0.213
0.304 0.18 0.162 0.238 0.189 0.264 0.256 0.156 0.195 0.249 0.214 0.212
0.243 0.192 0.179 0.213 0.204 0.262 0.272 0.178 0.203 0.289 0.209 0.207
0.243 0.197 0.193 0.252 0.205 0.24 0.262 0.185 0.21 0.284 0.221 0.207
0.223 0.202 0.201 0.212 0.226 0.251 0.25 0.197 0.227 0.297 0.207 0.209
0.231 0.194 0.202 0.209 0.219 0.234 0.236 0.187 0.226 0.29 0.21 0.209
0.225 0.208 0.204 0.2 0.214 0.219 0.23 0.194 0.207 0.239 0.202 0.203
0.234 0.214 0.21 0.214 0.217 0.223 0.241 0.203 0.212 0.205 0.202 0.224
Read 6 - Read 1
Averages: 0.256 0.198 0.193 0.225 0.211 0.243 0.257 0.187 0.212 0.262 0.209 0.211
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
LDH Release % 6.4547677 8.027813 8.911212 7.579123 8.456973 7.960966 6.532297 9.41689 8.658392 7.122371 8.965929 18.40855
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
Key Results
1 2 3 4 5 6 7 8 9 10 11 12
A 0.92 0.898 0.916 0.901 0.894 0.912 0.902 0.903 0.91 0.905 0.89 0.911 340 Read#1
B 0.88 0.901 0.896 0.894 0.899 0.902 0.902 0.908 0.901 0.914 0.901 0.9 340 Read#1
C 0.9 0.889 0.888 0.891 0.894 0.903 0.878 0.898 0.881 0.899 0.89 0.909 340 Read#1
D 0.889 0.889 0.883 0.905 0.897 0.9 0.899 0.908 0.9 0.907 0.903 0.897 340 Read#1
E 0.892 0.89 0.889 0.895 0.896 0.899 0.904 0.907 0.896 0.895 0.894 0.899 340 Read#1
F 0.886 0.87 0.886 0.881 0.905 0.886 0.917 0.908 0.885 0.905 0.893 0.889 340 Read#1
G 0.897 0.892 0.894 0.887 0.895 0.891 0.899 0.896 0.893 0.898 0.895 0.888 340 Read#1
H 0.891 0.882 0.887 0.893 0.887 0.888 0.892 0.89 0.897 0.899 0.887 0.892 340 Read#1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.884 0.874 0.864 0.873 0.864 0.87 0.875 0.875 0.879 0.869 0.847 0.849 340 Read#6
B 0.817 0.876 0.84 0.844 0.869 0.865 0.874 0.881 0.872 0.882 0.865 0.859 340 Read#6
C 0.861 0.861 0.842 0.863 0.863 0.868 0.854 0.866 0.849 0.869 0.859 0.877 340 Read#6
D 0.852 0.857 0.841 0.877 0.865 0.866 0.869 0.874 0.871 0.877 0.872 0.849 340 Read#6
E 0.86 0.858 0.853 0.862 0.862 0.869 0.874 0.874 0.865 0.862 0.869 0.858 340 Read#6
F 0.852 0.834 0.851 0.852 0.879 0.853 0.888 0.872 0.853 0.877 0.869 0.836 340 Read#6
G 0.865 0.865 0.863 0.855 0.868 0.867 0.87 0.87 0.868 0.86 0.858 0.833 340 Read#6
H 0.853 0.849 0.861 0.858 0.841 0.852 0.863 0.86 0.87 0.873 0.846 0.841 340 Read#6
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Raw Data - Plate T 
 
 
 
 
 
 
 
 
 
 
0.036 0.024 0.052 0.028 0.03 0.042 0.027 0.028 0.031 0.036 0.043 0.062
0.063 0.025 0.056 0.05 0.03 0.037 0.028 0.027 0.029 0.032 0.036 0.041
0.039 0.028 0.046 0.028 0.031 0.035 0.024 0.032 0.032 0.03 0.031 0.032
0.037 0.032 0.042 0.028 0.032 0.034 0.03 0.034 0.029 0.03 0.031 0.048
0.032 0.032 0.036 0.033 0.034 0.03 0.03 0.033 0.031 0.033 0.025 0.041
0.034 0.036 0.035 0.029 0.026 0.033 0.029 0.036 0.032 0.028 0.024 0.053
0.032 0.027 0.031 0.032 0.027 0.024 0.029 0.026 0.025 0.038 0.037 0.055
0.038 0.033 0.026 0.035 0.046 0.036 0.029 0.03 0.027 0.026 0.041 0.051
Read 6 - Read 1
Averages: 0.039 0.030 0.041 0.033 0.032 0.034 0.028 0.031 0.030 0.032 0.034 0.048
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
1 2 3 4 5 6 7 8 9 10 11 12
A 0.775 0.825 0.844 0.819 0.804 0.817 0.821 0.821 0.838 0.849 0.845 0.87 340 Read#1
B 0.784 0.827 0.844 0.812 0.807 0.815 0.832 0.833 0.836 0.853 0.861 0.853 340 Read#1
C 0.774 0.816 0.845 0.814 0.825 0.828 0.815 0.825 0.823 0.839 0.84 0.851 340 Read#1
D 0.765 0.825 0.847 0.806 0.805 0.809 0.813 0.824 0.833 0.841 0.854 0.847 340 Read#1
E 0.763 0.829 0.849 0.809 0.799 0.817 0.811 0.819 0.836 0.835 0.851 0.843 340 Read#1
F 0.738 0.813 0.844 0.785 0.782 0.803 0.807 0.832 0.822 0.832 0.844 0.84 340 Read#1
G 0.745 0.825 0.843 0.794 0.799 0.823 0.805 0.819 0.842 0.825 0.854 0.843 340 Read#1
H 0.744 0.808 0.818 0.776 0.78 0.822 0.806 0.811 0.838 0.833 0.85 0.861 340 Read#1
1 2 3 4 5 6 7 8 9 10 11 12
A 0.414 0.631 0.653 0.527 0.446 0.478 0.466 0.485 0.495 0.548 0.536 0.523 340 Read#6
B 0.492 0.643 0.709 0.54 0.479 0.52 0.534 0.529 0.501 0.565 0.61 0.519 340 Read#6
C 0.454 0.622 0.712 0.569 0.538 0.579 0.543 0.546 0.538 0.529 0.611 0.521 340 Read#6
D 0.45 0.654 0.723 0.525 0.473 0.541 0.523 0.552 0.572 0.567 0.642 0.501 340 Read#6
E 0.454 0.665 0.741 0.551 0.501 0.566 0.543 0.562 0.604 0.551 0.648 0.563 340 Read#6
F 0.402 0.668 0.73 0.518 0.476 0.567 0.533 0.597 0.596 0.568 0.656 0.547 340 Read#6
G 0.409 0.67 0.738 0.532 0.546 0.617 0.527 0.593 0.669 0.577 0.691 0.622 340 Read#6
H 0.438 0.642 0.645 0.492 0.525 0.645 0.56 0.586 0.661 0.624 0.697 0.722 340 Read#6
0.361 0.194 0.191 0.292 0.358 0.339 0.355 0.336 0.343 0.301 0.309 0.347
0.292 0.184 0.135 0.272 0.328 0.295 0.298 0.304 0.335 0.288 0.251 0.334
0.32 0.194 0.133 0.245 0.287 0.249 0.272 0.279 0.285 0.31 0.229 0.33
0.315 0.171 0.124 0.281 0.332 0.268 0.29 0.272 0.261 0.274 0.212 0.346
0.309 0.164 0.108 0.258 0.298 0.251 0.268 0.257 0.232 0.284 0.203 0.28
0.336 0.145 0.114 0.267 0.306 0.236 0.274 0.235 0.226 0.264 0.188 0.293
0.336 0.155 0.105 0.262 0.253 0.206 0.278 0.226 0.173 0.248 0.163 0.221
0.306 0.166 0.173 0.284 0.255 0.177 0.246 0.225 0.177 0.209 0.153 0.139
Read 6 - Read 1
Averages: 0.322 0.172 0.135 0.270 0.302 0.253 0.285 0.267 0.254 0.272 0.214 0.286
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
LDH Release % 6.038835 8.630736 14.95845 6.085146 5.295821 6.704602 4.953968 5.763824 5.807087 5.808081 7.845433 8.362445
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
Key Results
Average LDH Release % 5.9949669 7.959816 9.583785 6.64868 7.641039 10.35914
STDEV 0.7270362 1.570584 3.849639 0.839501 1.629203 5.412538
Concentration (uM) 0 4 6 8 10 12
Final Results
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Table A6. Key results collected from LDH release assay on Crizotinib (Drug 25) treated hepatocytes. Hepatocytes 
were treated is Crizotinib for 8 h prior to LDH release assay. Data collected and formulated was used in part to 
create Figure 5. 
Date 6/22/2015 
Rat Sex Female 
Rat DOB 3/28/2014 
Rat BW 490 
Perfusion Results Good 
    
    
Drug 25 
LDH Release Assay   
Time 8h 
 
 
 
 
 
Table A7. Key results collected from LDH release assay on Ceritinib (Drug 51) treated hepatocytes. Hepatocytes 
were treated is Ceritinib for 24 h prior to LDH release assay. Data collected and formulated was used in part to 
create Figure 6. Red cell denotes outlier removed. 
 
 
LDH Release % 6.1601151 9.625323 9.82641 15.81832 13.39564 29.43677 7.26884 12.02866 10.46718 12.09877 17.57493 45.08561
Drug Concentration (uM) 0 10 15 20 25 30 0 10 15 20 25 30
Key Results - Replicate 1
LDH Release % 9.9350649 8.010563 11.42749 17.16141 30.06024 30.48259 7.990379 11.67532 15.20241 14.63981 9.801678 30.91174
Drug Concentration (uM) 0 10 15 20 25 30 0 10 15 20 25 30
Key Results - Replicate 2
Average LDH Release % 7.8385999 10.33496 11.73087 14.92958 17.70812 33.97918
STDEV 1.5874655 1.877194 2.40607 2.15007 8.826134 7.430153
Concentration (uM) 0 10 15 20 25 30
Final Results
Date 6/22/2015
Rat Sex Female
Rat DOB 3/28/2014
Rat BW 490
Perfusion Results Good
Drug 51
LDH Release Assay
Time 24h
LDH Release % 9.624697337 18.45372 13.46877 9.73172 15.09669 48.36538 8.852868 8.691309 7.94347 8.219822 11.61593 54.25466
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
Key Results - Replicate 1
24 
 
 
 
 
Table A8. Key results collected from LDH release assay on Crizotinib (Drug 25) treated hepatocytes. Hepatocytes 
were treated is Crizotinib for 24 h prior to LDH release assay. Data collected and formulated was used in part to 
create Figure 5. 
Date 6/22/2015 
Rat Sex Female 
Rat DOB 3/28/2014 
Rat BW 490 
Perfusion Results Good 
    
    
Drug 25 
LDH Release Assay   
Time 24h 
 
 
 
 
LDH Release % 18.91891892 12.22642 24.19106 10.40222 12.73458 18.51201 11.6092 70.94595 17.70701 38.86256 12.40132 36.08826
Drug Concentration (uM) 0 4 6 8 10 12 0 4 6 8 10 12
Key Results
Average LDH Release % 12.25141987 13.12382 15.82758 16.80408 12.96213 39.30508
STDEV 4.594120266 4.94269 6.860594 14.73395 1.498323 15.79323
Concentration (uM) 0 4 6 8 10 12
Final Results
LDH Release % 9.601936525 10.05155 26.0631 20.31767 37.14722 53.12316 7.933923 6.667986 7.883495 17.19506 23.50092 65.727
Drug Concentration (uM) 0 10 15 20 25 30 0 10 15 20 25 30
Key Results - Replicate 1
LDH Release % 45.65217391 86.73469 87.43017 22.22696 85.08772 64.90066 6.215084 21.50706 61.30268 26.35359 68.82353 96.54822
Drug Concentration (uM) 0 10 15 20 25 30 0 10 15 20 25 30
Key Results - Replicate 2
Average LDH Release % 17.35077925 31.24032 45.66986 21.52332 53.63985 70.07476
STDEV 18.91819585 37.53721 35.5928 3.830322 28.28353 18.56408
Concentration (uM) 0 10 15 20 25 30
Final Results
